Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2012, Article ID 782672, 9 pages
http://dx.doi.org/10.1155/2012/782672
Review Article

Surgical Treatment of Liver Metastases in Neuroendocrine Neoplasms

1Department of Surgical Oncology, Lilavati Hospital & Research Centre, Mumbai 400 050, India
2Department of Surgical Oncology, Dr. L. H. Hiranandani Hospital and Research Centre, Mumbai 400 076, India
3Department of Gastrointestinal Surgical Oncology, Tata Memorial Hospital, Mumbai 400 012, India

Received 15 July 2011; Accepted 7 October 2011

Academic Editor: Wouter de Herder

Copyright © 2012 Palepu Jagannath et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Rindi, G. Klöppel, H. Alhman et al., “TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system,” Virchows Archiv, vol. 449, no. 4, pp. 395–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Rindi, G. Klöppel, A. Couvelard et al., “TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system,” Virchows Archiv, vol. 451, no. 4, pp. 757–762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. F. Bosman, F. Carneiro, R. Hruban et al., WHO Classification of Tumors of the Digestive System, IARC Press, Lyon, France, 2010.
  4. M. S. Talamonti, K. Stuart, and J. C. Yao, “Neuroendocrine tumors of the gastrointestinal tract: how aggressive should we be?” in American Society of Clinical Oncology 2004 Education Book, M. Perry, Ed., pp. 206–215, American Society of Clinical Oncology, Alexandria, Egypt, 2004. View at Google Scholar
  5. M. A. Kouvaraki, J. A. Ajani, P. Hoff et al., “Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas,” Journal of Clinical Oncology, vol. 22, no. 23, pp. 4762–4771, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. P. Venook, “Embolization and chemoembolization therapy for neuroendocrine tumors,” Current Opinion in Oncology, vol. 11, no. 1, pp. 38–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. I. M. Modlin, K. D. Lye, and M. Kidd, “A 5-decade analysis of 13,715 carcinoid tumors,” Cancer, vol. 97, no. 4, pp. 934–959, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. F. R. Norheim, K. Oberg, and E. Theodorsson-Norheim, “Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival,” Annals of Surgery, vol. 206, no. 2, pp. 115–125, 1987. View at Google Scholar · View at Scopus
  9. K. Oberg and B. Eriksson, “Endocrine tumors of pancreas,” Best Practice & Research Clinical Gastroenterology, vol. 19, pp. 753–781, 2005. View at Google Scholar
  10. J. G. Touzios, J. M. Kiely, S. C. Pitt et al., “Neuroendocrine hepatic metastases: does aggressive management improve survival?” Annals of Surgery, vol. 241, no. 5, pp. 776–785, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. L. F. Starker and T. Carling, “Molecular genetics of gastroenteropancreatic neuroendocrine tumors,” Current Opinion in Oncology, vol. 21, no. 1, pp. 29–33, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. E. W. M. McDermott, B. Guduric, and M. F. Brennan, “Prognostic variables in patients with gastrointestinal carcinoid tumours,” British Journal of Surgery, vol. 81, no. 7, pp. 1007–1009, 1994. View at Publisher · View at Google Scholar · View at Scopus
  13. C. G. Moertel, W. G. Sauer, M. B. Dockerty, and A. H. Baggenstoss, “Life history of the carcinoid tumor of the small intestine,” Cancer, vol. 14, pp. 901–912, 1961. View at Google Scholar
  14. G. B. Thompson, J. A. van Heerden, C. S. Grant, J. A. Carney, and D. M. Ilstrup, “Islet cell carcinomas of the pancreas: a twenty-year experience,” Surgery, vol. 104, no. 6, pp. 1011–1017, 1988. View at Google Scholar · View at Scopus
  15. J. Zeitels, K. Naunheim, E. L. Kaplan, and F. Straus, “Carcinoid tumors. A 37-year experience,” Archives of Surgery, vol. 117, no. 5, pp. 732–737, 1982. View at Google Scholar · View at Scopus
  16. F. Panzuto, S. Nasoni, M. Falconi et al., “Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization,” Endocrine-Related Cancer, vol. 12, no. 4, pp. 1083–1092, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Madeira, B. Terris, M. Voss et al., “Prognostic factors in patients with endocrine tumours of the duodenopancreatic area,” Gut, vol. 43, no. 3, pp. 422–427, 1998. View at Google Scholar · View at Scopus
  18. P. Tomassetti, D. Campana, L. Piscitelli et al., “Endocrine pancreatic tumors: factors correlated with survival,” Annals of Oncology, vol. 16, no. 11, pp. 1806–1810, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Rindi, T. D'Adda, E. Froio, G. Fellegara, and C. Bordi, “Prognostic factors in gastrointestinal endocrine tumors,” Endocrine Pathology, vol. 18, no. 3, pp. 145–149, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Lepage, B. Rachet, and M. P. Coleman, “Survival from maliganant digestive neuroendocrine tumors in England and Wales: a population-based study,” Gatroenterology, vol. 132, pp. 899–904, 2007. View at Google Scholar
  21. F. Maire, A. Couvelard, M. P. Vullierme et al., “Primary endocrine tumours of the liver,” British Journal of Surgery, vol. 92, no. 10, pp. 1255–1260, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. D. C. Madoff, S. Gupta, K. Ahrar, R. Murthy, and J. C. Yao, “Update on the management of neuroendocrine hepatic metastases,” Journal of Vascular and Interventional Radiology, vol. 17, no. 8, pp. 1235–1250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. O. Nilsson, E. Van Cutsem, G. Delle Fave et al., “Consensus conference; European neuroendocrine tumor society: poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic),” Neuroendocrinology, vol. 84, no. 3, pp. 212–215, 2006. View at Publisher · View at Google Scholar
  24. J. A. Norton and R. T. Jensen, “Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome,” Annals of Surgery, vol. 240, no. 5, pp. 757–773, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. E. W. M. McDermott, B. Guduric, and M. F. Brennan, “Prognostic variables in patients with gastrointestinal carcinoid tumours,” British Journal of Surgery, vol. 81, no. 7, pp. 1007–1009, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. A. P. Burke, R. M. Thomas, A. M. Elsayed, and L. H. Sobin, “Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases,” Cancer, vol. 79, no. 6, pp. 1086–1093, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Soga, “Statistical evaluation of 2001 carcinoid cases with metastases, collected from literature: a comparative study between ordinary carcinoids and atypical varieties,” Journal of Experimental and Clinical Cancer Research, vol. 17, no. 1, pp. 3–12, 1998. View at Google Scholar · View at Scopus
  28. E. T. Janson, L. Holmberg, M. Stridsberg et al., “Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center,” Annals of Oncology, vol. 8, no. 7, pp. 685–690, 1997. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Norton, “Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases,” Best Practice & Research Clinical Gastroenterology, vol. 19, pp. 577–583, 2005. View at Google Scholar
  30. R. S. Chamberlain, D. Canes, K. T. Brown et al., “Hepatic neuroendocrine metastases: does intervention alter outcomes?” Journal of the American College of Surgeons, vol. 190, no. 4, pp. 432–445, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Frilling, J. Li, E. Malamutmann, K. W. Schmid, A. Bockisch, and C. E. Broelsch, “Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease,” British Journal of Surgery, vol. 96, no. 2, pp. 175–184, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Steinmüller, R. Kianmanesh, M. Falconi et al., “Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary,” Neuroendocrinology, vol. 87, no. 1, pp. 47–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. I. Ihse, B. Persson, and S. Tibblin, “Neuroendocrine metastases of the liver,” World Journal of Surgery, vol. 19, no. 1, pp. 76–82, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. J. L. Fidler, J. G. Fletcher, C. C. Reading et al., “Preoperative detection of pancreatic insulinomas on multiphasic helical CT,” American Journal of Roentgenology, vol. 181, no. 3, pp. 775–780, 2003. View at Google Scholar · View at Scopus
  35. A. D. King, G. T. C. Ko, V. T. F. Yeung, C. C. Chow, J. Griffith, and C. S. Cockram, “Dual phase spiral CT in the detection of small insulinomas of the pancreas,” British Journal of Radiology, vol. 71, pp. 20–23, 1998. View at Google Scholar · View at Scopus
  36. T. Ichikawa, M. S. Peterson, M. P. Federle et al., “Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection,” Radiology, vol. 216, no. 1, pp. 163–171, 2000. View at Google Scholar · View at Scopus
  37. L. Van Hoe, S. Gryspeerdt, G. Marchal, A. L. Baert, and L. Mertens, “Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images,” American Journal of Roentgenology, vol. 165, no. 6, pp. 1437–1439, 1995. View at Google Scholar · View at Scopus
  38. C. Dromain, T. De Baere, J. Lumbroso et al., “Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging,” Journal of Clinical Oncology, vol. 23, no. 1, pp. 70–78, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. E. P. Krenning, D. J. Kwekkeboom, W. H. Bakker et al., “Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients,” European Journal of Nuclear Medicine, vol. 20, no. 8, pp. 716–731, 1993. View at Google Scholar · View at Scopus
  40. F. Gibril, J. C. Reynolds, J. L. Doppman et al., “Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas—a prospective study,” Annals of Internal Medicine, vol. 125, no. 1, pp. 26–34, 1996. View at Google Scholar · View at Scopus
  41. D. J. Kwekkeboom, E. P. Krenning, K. Scheidhauer et al., “ENETS consensus guidelines for the standards of care in neuroendocrine tumors: somatostatin receptor imaging with 111In-pentetreotide,” Neuroendocrinology, vol. 90, no. 2, pp. 184–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. D. T. O'Connor and L. J. Deftos, “Secretion of chromogranin A by peptide-producing endocrine neoplasms,” New England Journal of Medicine, vol. 314, no. 18, pp. 1145–1151, 1986. View at Google Scholar · View at Scopus
  43. K. Öberg and M. Stridsberg, “Chromogranins as diagnostic and prognostic markers in neuroendocrine tumours,” Advances in Experimental Medicine and Biology, vol. 482, pp. 329–337, 2000. View at Google Scholar · View at Scopus
  44. E. Baudin, J. M. Bidart, A. Bachelot et al., “Impact of chromogranin A measurement in the work-up of neuroendocrine tumors,” Annals of Oncology, vol. 12, supplement 2, pp. S79–S82, 2001. View at Google Scholar · View at Scopus
  45. P. Tomassetti, M. Migliori, P. Simoni et al., “Diagnostic value of plasma chromogranin A in neuroendocrine tumours,” European Journal of Gastroenterology and Hepatology, vol. 13, no. 1, pp. 55–58, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. M. C. Zatelli, M. Torta, A. Leon et al., “Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study,” Endocrine-Related Cancer, vol. 14, no. 2, pp. 473–482, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Sutcliffe, D. Maguire, J. Ramage, M. Rela, and N. Heaton, “Management of neuroendocrine liver metastases,” American Journal of Surgery, vol. 187, no. 1, pp. 39–46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. K. S. Gurusamy, V. Pamecha, D. Sharma, and B. R. Davidson, “Techniques for liver parenchymal transection in liver resection,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD006880, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. K. S. Gurusamy, V. Pamecha, D. Sharma, and B. R. Davidson, “Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours,” Cochrane Database of Systematic Reviews, no. 1, Article ID CD007118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. T. J. Vogl, N. N. N. Naguib, S. Zangos, K. Eichler, A. Hedayati, and N. E. A. Nour-Eldin, “Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation,” European Journal of Radiology, vol. 72, no. 3, pp. 517–528, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. I. Ihse, B. Persson, and S. Tibblin, “Neuroendocrine metastases of the liver,” World Journal of Surgery, vol. 19, no. 1, pp. 76–82, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Frilling, G. C. Sotiropoulos, J. Li, O. Kornasiewicz, and U. Plöckinger, “Multimodal management of neuroendocrine liver metastases,” International Hepato-Pancreato-Biliary Association, vol. 12, no. 6, pp. 361–379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. J. M. Sarmiento, G. Heywood, J. Rubin, D. M. Ilstrup, D. M. Nagorney, and F. G. Que, “Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival,” Journal of the American College of Surgeons, vol. 197, no. 1, pp. 29–37, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. J. M. Sarmiento and F. G. Que, “Hepatic surgery for metastases from neuroendocrine tumors,” Surgical Oncology Clinics of North America, vol. 12, no. 1, pp. 231–242, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Elias, P. Lasser, M. Ducreux et al., “Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study,” Surgery, vol. 133, no. 4, pp. 375–382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. H. Chen, J. M. Hardacre, A. Uzar, J. L. Cameron, and M. A. Choti, “Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?” Journal of the American College of Surgeons, vol. 187, no. 1, pp. 88–93, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. M. G. House, J. L. Cameron, K. D. Lillemoe et al., “Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer,” Journal of Gastrointestinal Surgery, vol. 10, no. 1, pp. 138–145, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. S. C. Mayo, M. C. de Jong, C. Pulitano et al., “Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis,” Annals of Surgical Oncology, vol. 17, pp. 3129–3136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. E. S. Glazer, J. F. Tseng, W. Al-Refaie et al., “Long-term survival after surgical management of neuroendocrine hepatic metastases,” International Hepato-Pancreato-Biliary Association, vol. 12, no. 6, pp. 427–433, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. K. A. Yao, M. S. Talamonti, A. Nemcek et al., “Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors,” Surgery, vol. 130, no. 4, pp. 677–685, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. S. Musunuru, H. Chen, S. Rajpal et al., “Metastatic neuroendocrine hepatic tumors: resection improves survival,” Archives of Surgery, vol. 141, no. 10, pp. 1000–1005, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. G. L. Grazi, M. Cescon, F. Pierangeli et al., “Highly aggressive policy of hepatic resections for neuroendocrine liver metastases,” Hepato-Gastroenterology, vol. 47, no. 32, pp. 481–486, 2000. View at Google Scholar · View at Scopus
  63. C. S. Cho, D. M. Labow, L. Tang et al., “Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms,” Cancer, vol. 113, no. 1, pp. 126–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. J. C. Yao and J. N. Vauthey, “Primary and metastatic hepatic carcinoid: is there an algorithm?” Annals of Surgical Oncology, vol. 10, no. 10, pp. 1133–1135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. K. Öberg, L. Kvols, M. Caplin et al., “Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system,” Annals of Oncology, vol. 15, no. 6, pp. 966–973, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. P. A. Farling and A. K. Durairaju, “Remifentanil and anaesthesia for carcinoid syndrome,” British Journal of Anaesthesia, vol. 92, no. 6, pp. 893–895, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Scigliano, R. Lebtahi, F. Maire et al., “Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience,” Endocrine-Related Cancer, vol. 16, no. 3, pp. 977–990, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. D. Gomez, H. Z. Malik, A. Al-Mukthar et al., “Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors,” International Hepato-Pancreato-Biliary Association, vol. 9, no. 5, pp. 345–351, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. National Comprehensive Cancer Network (NCCN), 2011, http://www.nccn.org/index.asp.
  70. S. A. Gulec, T. S. Mountcastle, D. Frey et al., “Cytoreductive surgery in patients with advanced-stage carcinoid tumors,” American Surgeon, vol. 68, no. 8, pp. 667–671, 2002. View at Google Scholar · View at Scopus
  71. R. Kianmanesh, A. Sauvanet, O. Hentic et al., “Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection,” Annals of Surgery, vol. 247, no. 4, pp. 659–665, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. D. Jaeck, E. Oussoultzoglou, P. Bachellier et al., “Hepatic metastases of gastroenteropancreatic neuroendocrine tumors: safe hepatic surgery,” World Journal of Surgery, vol. 25, no. 6, pp. 689–692, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. C. S. Landry, C. R. Scoggins, K. M. Mcmasters, and R. C. G. Martin, “Management of hepatic metastasis of gastrointestinal carcinoid tumors,” Journal of Surgical Oncology, vol. 97, no. 3, pp. 253–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. D. A. Osborne, E. E. Zervos, J. Strosberg et al., “Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors,” Annals of Surgical Oncology, vol. 13, no. 4, pp. 572–581, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Musunuru, H. Chen, S. Rajpal et al., “Metastatic neuroendocrine hepatic tumors: resection improves survival,” Archives of Surgery, vol. 141, no. 10, pp. 1000–1004, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. C. D. Knox, I. D. Feurer, P. E. Wise et al., “Survival and functional quality of life after resection for hepatic carcinoid metastasis,” Journal of Gastrointestinal Surgery, vol. 8, no. 6, pp. 653–659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Givi, S. J. Pommier, A. K. Thompson, B. S. Diggs, and R. F. Pommier, “Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival,” Surgery, vol. 140, no. 6, pp. 891–898, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. O. Soreide, T. Berstad, A. Bakka et al., “Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors,” Surgery, vol. 111, no. 1, pp. 48–54, 1992. View at Google Scholar · View at Scopus
  79. H. Ahlman, B. Wängberg, S. Jansson et al., “Interventional treatment of gastrointestinal neuroendocrine tumours,” Digestion, vol. 62, supplement 1, pp. 59–68, 2000. View at Google Scholar · View at Scopus
  80. F. G. Que, D. M. Nagorney, K. P. Batts, L. J. Linz, and L. K. Kvols, “Hepatic resection for metastatic neuroendocrine carcinomas,” American Journal of Surgery, vol. 169, no. 1, pp. 36–43, 1995. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Clary, “Treatment of isolated neuroendocrine liver metastases,” Journal of Gastrointestinal Surgery, vol. 10, no. 3, pp. 332–334, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. A. E. Siperstein, S. J. Rogers, P. D. Hansen, and A. Gitomirsky, “Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases,” Surgery, vol. 122, no. 6, pp. 1147–1155, 1997. View at Publisher · View at Google Scholar · View at Scopus
  83. A. E. Siperstein and E. Berber, “Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases,” World Journal of Surgery, vol. 25, no. 6, pp. 693–696, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. P. J. Mazzaglia, E. Berber, M. Milas, and A. E. Siperstein, “Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival,” Surgery, vol. 142, no. 1, pp. 10–19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. E. Berber, N. Flesher, and A. E. Siperstein, “Laparoscopic radiofrequency ablation of neuroendocrine liver metastases,” World Journal of Surgery, vol. 26, no. 8, pp. 985–990, 2002. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Livraghi, S. N. Goldberg, S. Lazzaroni et al., “Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions,” Radiology, vol. 214, no. 3, pp. 761–768, 2000. View at Google Scholar · View at Scopus
  87. H. Nave, E. Mössinger, H. Feist, H. Lang, and H. R. Raab, “Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years,” Surgery, vol. 129, no. 2, pp. 170–175, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Saxena, T. C. Chua, F. Chu et al., “Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation,” American Journal of Clinical Oncology. In press.
  89. T. M. Pawlik, F. Izzo, D. S. Cohen, J. S. Morris, and S. A. Curley, “Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients,” Annals of Surgical Oncology, vol. 10, no. 9, pp. 1059–1069, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Evrard, Y. Becouarn, M. Fonck, R. Brunet, S. Mathoulin-Pelissier, and V. Picot, “Surgical treatment of liver metastases by radiofrequency ablation, resection, or in combination,” European Journal of Surgical Oncology, vol. 30, no. 4, pp. 399–406, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. B. Fioole, M. C. Jansen, F. H. van Duijnhoven, R. van Hillegersberg, T. M. van Gulik, and I. H. M. Borel Rinkes, “Combining partial liver resection and local ablation of liver tumours: a preliminary Dutch experience,” World Journal of Surgical Oncology, vol. 4, article 46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. D. Elias, D. Goéré, G. Leroux et al., “Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver,” European Journal of Surgical Oncology, vol. 35, no. 10, pp. 1092–1097, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. D. O'Toole and P. Ruszniewski, “Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours,” Best Practice and Research, vol. 19, no. 4, pp. 585–594, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. S. Gupta, M. M. Johnson, R. Murthy et al., “Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival,” Cancer, vol. 104, no. 8, pp. 1590–1602, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. D. A. Osborne, E. E. Zervos, J. Strosberg et al., “Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors,” Annals of Surgical Oncology, vol. 13, no. 4, pp. 572–581, 2006. View at Publisher · View at Google Scholar · View at Scopus
  96. A. S. Ho, J. Picus, M. D. Darcy et al., “Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors,” American Journal of Roentgenology, vol. 188, no. 5, pp. 1201–1207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Proye, “Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization,” World Journal of Surgery, vol. 25, no. 6, pp. 685–688, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. P. Le Treut, E. Grégoire, J. Belghiti et al., “Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report,” American Journal of Transplantation, vol. 8, no. 6, pp. 1205–1213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. F. G. I. van Vilsteren, E. S. Baskin-Bey, D. M. Nagorney et al., “Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival,” Liver Transplantation, vol. 12, no. 3, pp. 448–456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  100. Y. P. Le Treut, J. R. Delpero, B. Dousset et al., “Results of liver transplantation in the treatment of metastatic neuroendocrine tumors: a 31-case French multicentric report,” Annals of Surgery, vol. 225, no. 4, pp. 355–364, 1997. View at Publisher · View at Google Scholar · View at Scopus
  101. B. Dousset, O. Saint-Marc, J. Pitre, O. Soubrane, D. Houssin, and Y. Chapuis, “Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation,” World Journal of Surgery, vol. 20, no. 7, pp. 908–915, 1996. View at Publisher · View at Google Scholar
  102. T. Lehnert, “Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients,” Transplantation, vol. 66, no. 10, pp. 1307–1312, 1998. View at Google Scholar · View at Scopus
  103. W. O. Bechstein and P. Neuhaus, “Liver transplantation for hepatic metastases of neuroendocrine tumors,” Annals of the New York Academy of Sciences, vol. 733, pp. 507–514, 1994. View at Publisher · View at Google Scholar · View at Scopus
  104. D. Routley, J. K. Ramage, J. McPeake, K. C. Tan, and R. Williams, “Orthotopic liver transplantation in the treatment of metastatic neuroendocrine tumors of the liver,” Liver Transplantation and Surgery, vol. 1, no. 2, pp. 118–121, 1995. View at Google Scholar · View at Scopus
  105. W. C. Blonski, K. R. Reddy, A. Shaked, E. Siegelman, and D. C. Metz, “Liver transplantation for metastatic neuroendocrine tumor: a case report and review of the literature,” World Journal of Gastroenterology, vol. 11, no. 48, pp. 7676–7683, 2005. View at Google Scholar · View at Scopus
  106. V. Mazzaferro, A. Pulvirenti, and J. Coppa, “Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation?” Journal of Hepatology, vol. 47, no. 4, pp. 460–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  107. S. K. Reddy and B. M. Clary, “Neuroendocrine liver metastases,” Surgical Clinics of North America, vol. 90, no. 4, pp. 853–861, 2010. View at Publisher · View at Google Scholar · View at Scopus